# AbCellera Biologics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/abcellera-biologics

- Industry: Biotechnology
- Headquarters: Vancouver, Canada
- Website: www.abcellera.com
- Total disclosed funding: $115M
- Latest round: Series B (May 27, 2020)
- Investors on record: 7

## About

AbCellera Biologics Inc. is a biotechnology company focused on antibody discovery and development, utilizing an innovative platform that combines biology, computation, and engineering to create advanced therapeutics.Founded in 2012 in Vancouver, Canada, AbCellera Biologics Inc. specializes in developing innovative antibody-based therapeutics. The company raised USD 483 mn in its IPO on December 10, 2020, selling 24.15 million shares at USD 20 per share on the Nasdaq. The firm has completed 11 deals to date. The co-founders, Kathleen Lisaingo and Véronique Lecault, have established a strong foundation for the company alongside current CEO Carl Hansen.AbCellera specializes in the development of innovative antibody-based therapeutics, leveraging its advanced technology platform that integrates biology, computation, and engineering. The company’s primary focus is on creating first-in-class and best-in-class monoclonal antibodies for a range of health conditions, including endocrine disorders and autoimmune diseases. Notable products in their pipeline include ABCL635, an antibody targeting NK3R for the treatment of vasomotor symptoms associated with menopause, and ABCL575, which targets OX40L for moderate-to-severe atopic dermatitis. AbCellera collaborates with over 40 partners, serving biopharmaceutical companies globally, particularly in North America and Europe, to address complex medical challenges through its proprietary technology and development processes.AbCellera's revenue for the most recent year, 2023, amounted to USD 38.03 mn, while it reported an EBITDA loss of USD 206.31 mn. The company’s revenue model is primarily driven by partnerships with biopharmaceutical companies, which engage the firm for its expertise in antibody discovery and development. Transactions typically occur through collaborative agreements where clients fund specific projects, thereby sharing in the potential commercialization of the resulting therapeutics. The structure of these agreements may include milestone payments linked to the achievement of development stages, along with royalties on future sales of the developed products. The company’s flagship programs, such as ABCL635 and ABCL575, play a central role in these agreements, as they represent advancements in therapeutic offerings within their respective markets.AbCellera plans to enhance its product pipeline with new therapeutics in development, aiming for significant advancements in treatment options for various health conditions. The company is focused on expanding its reach into additional global markets, particularly in Europe and Asia, with initiatives expected to ramp up over the next few years. The recent IPO funding of USD 483 mn will support these growth strategies, providing the necessary capital for R&D and operational expansion. This investment will facilitate the launch and development of new products in their pipeline, which are anticipated to play a crucial role in the company's future trajectory.

## Funding rounds

- Series B, May 27, 2020, $105M — OrbiMed Advisors, Founders Fund, Viking Global Investors, Eli Lilly & Company, DCVC, University of Minnesota, Presight Capital
- Series A, Sep 27, 2018, $10M — DCVC

## Investors

- DCVC (https://capitalatlas.ai/funds/dcvc) — Series A, Series B
- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series B
- Founders Fund (https://capitalatlas.ai/funds/founders-fund) — Series B
- Viking Global Investors (https://capitalatlas.ai/funds/viking-global-investors) — Series B
- Eli Lilly & Company — Series B
- University of Minnesota — Series B
- Presight Capital — Series B